A randomized, 30 week, active-controlled, open-label, 3-treatment arm, parallel-group multicenter study comparing the efficacy and safety of insulin glargine/ lixisenatide fixed ratio combination to insulin glargine alone and to lixisenatide alone on top of metformin in patients with Type 2 diabetes mellitus

Trial Profile

A randomized, 30 week, active-controlled, open-label, 3-treatment arm, parallel-group multicenter study comparing the efficacy and safety of insulin glargine/ lixisenatide fixed ratio combination to insulin glargine alone and to lixisenatide alone on top of metformin in patients with Type 2 diabetes mellitus

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Insulin-glargine/lixisenatide (Primary) ; Insulin glargine; Lixisenatide; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms LixiLan-O
  • Sponsors Sanofi
  • Most Recent Events

    • 13 Jun 2017 Results of propensity score-matched analysis to compare this study and GetGoal Duo-1 Trial presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 13 Jun 2017 Results of dose capping data from two phase III studies (LixiLan-L and LixiLan-O) presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 13 Jun 2017 Results of a post-hoc analysis from LixiLan-O and LixiLan-L trials assessing time to glycemic control with lixisenatide/insulin glargine vs. insulin glargine alone in patients with type 2 diabetes mellitus, presented at the 77th Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top